patients with and without granulocytopenia. Antimicrobial Agents and Chemotherapy 1984;870-5. 48 Raad II, Escalante C, Hachem R Y, Hanna H A, Husni R, Afif C, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003;1039-47. 49 Reed R L I, Ericsson C D, Wu A, Miller-Crotchett P, Fischer R P. The pharmacokinetics of prophylactic antibiotics in trauma. The Journal of Trauma 1992;21-7. 50 Santré C, Georges H, Jacquier J M, Leroy O, Beuscart C, Buguin D, et al. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrobial Agents and Chemotherapy 1995;264-7. 51 Van der Auwera P. Pharmacokinetic evaluation of single daily dose amikacin. Journal of Antimicrobial Chemotherapy 1991;Supplement C 63-71. 52 Vanhaeverbeek M, Siska G, Douchamps J, Herchuelz A. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. International Journal of Clinical Pharmacology, Therapy and Toxicology 1993;31(3):153-6. 53 Wiland P, Szechcinski J. Proximal tubule damage in patients treated with gentamicin or amikacin. Polish Journal of Pharmacology 2003;631-7. Figure S 2: Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
patients with and without granulocytopenia. Antimicrobial Agents and Chemotherapy 1984;870-5. 48 Raad II, Escalante C, Hachem R Y, Hanna H A, Husni R, Afif C, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003;1039-47. 49 Reed R L I, Ericsson C D, Wu A, Miller-Crotchett P, Fischer R P. The pharmacokinetics of prophylactic antibiotics in trauma. The Journal of Trauma 1992;21-7. 50 Santré C, Georges H, Jacquier J M, Leroy O, Beuscart C, Buguin D, et al. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrobial Agents and Chemotherapy 1995;264-7. 51 Van der Auwera P. Pharmacokinetic evaluation of single daily dose amikacin. Journal of Antimicrobial Chemotherapy 1991;Supplement C 63-71. 52 Vanhaeverbeek M, Siska G, Douchamps J, Herchuelz A. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. International Journal of Clinical Pharmacology, Therapy and Toxicology 1993;31(3):153-6. 53 Wiland P, Szechcinski J. Proximal tubule damage in patients treated with gentamicin or amikacin. Polish Journal of Pharmacology 2003;631-7. Figure S 2: Risk of bias summary: review authors' judgements about each risk of bias item for each included study.